| Budget Amount *help |
¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2012: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Outline of Final Research Achievements |
In this study, we developed the novel melanoma vaccine and malaria vaccine using spleen-targeted nano-device. We used pUb-M which expresses melanoma-related antigen (gp100 and tyrosinase-related protein 2 (TRP2)) as melanoma DNA vaccine. We successfully prepared the stable nanoparticles (pUb-M/PEI/γ-PGA complexes) by optimization of the mix ratio. The pUb-M/PEI/γ-PGA complex significantly inhibited the growth and metastasis of a melanoma cell line, B16-F10 cells, and improved the survival time of metastasis model mice. For the development of malaria DNA nano-vaccine, PyGPI8p-transamidase-related protein (PyTAM) was selected as a possible candidate vaccine antigen. The pyTAM/PEI/γ-PGA complexes suppressed parasitemia and prolonged survival.
|
